- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- February 2024
- 204 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1204EUR$1,250USD£1,036GBP
- Report
- March 2024
- 164 Pages
Global
From €7661EUR$7,950USD£6,590GBP
- Report
- January 2021
- 600 Pages
United States
From €2698EUR$2,800USD£2,321GBP
- Report
- January 2023
- 150 Pages
United States
From €3806EUR$3,950USD£3,274GBP
- Report
- January 2021
- 900 Pages
United States
From €3180EUR$3,300USD£2,735GBP
- Report
- January 2022
- 121 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3132EUR$3,250USD£2,694GBP
- Report
- July 2021
- 50 Pages
China
From €2505EUR$2,600USD£2,155GBP
- Report
- May 2023
- 114 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- May 2024
- 50 Pages
Global
From €2554EUR$2,650USD£2,197GBP
- Report
- July 2023
- 98 Pages
China
From €1734EUR$1,800USD£1,492GBP
- Report
- July 2023
- 199 Pages
China
From €3854EUR$4,000USD£3,315GBP
- Report
- August 2020
- 113 Pages
Global
From €4336EUR$4,500USD£3,730GBP
Capecitabine is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of oral chemotherapy, meaning it is taken in pill form. Capecitabine works by blocking the growth of cancer cells and preventing them from dividing and spreading. It is often used in combination with other chemotherapy drugs to increase the effectiveness of treatment. Capecitabine is generally well-tolerated, with fewer side effects than other chemotherapy drugs.
Capecitabine is a relatively new drug, first approved by the FDA in 1998. It is now widely used in the treatment of NSCLC, and is often prescribed in combination with other chemotherapy drugs. It is also used to treat other types of cancer, such as breast cancer and colorectal cancer.
In the Capecitabine market, some of the major players include Roche, Pfizer, Merck, AstraZeneca, and Bristol-Myers Squibb. These companies manufacture and distribute the drug, as well as provide support services to healthcare providers and patients. Show Less Read more